Trading Statement

Oxford Pharmascience Group plc

("Oxford Pharmascience" or "the Company")

Oxford Pharmascience Group Plc Trading Update

Oxford Pharmascience (AIM: OXP), the specialty pharmaceutical company that redevelops medicines to make them better, safer and easier to take, today announces a pre-close trading statement for the year ended 31 December 2013.

Revenue for the year ended 31 December 2013 is expected to have grown to approximately £1.02m up 122% from £0.46m in 2012, whilst adjusted loss (before share based payments, depreciation, amortisation and transaction related costs) is expected to show an increase of approximately 86% from -£0.81 in 2012 to -£1.51m.

Revenue from sales of its chew products in Brazil continues to grow strongly; the increase in adjusted loss reflects the company's increased expenditure on research and development for its NSAIDs (Non-steroidal anti-inflammatory drugs) program for which clinical trials will be starting in Q2 2014.

After two successful fund raisings in 2013 the company has cash resources available amounting to £9.6m

Nigel Theobald, CEO of Oxford Pharmascience commented

"The progress we have made in 2013 has been fantastic. We have strengthened our team with some key appointments and made considerable progress towards commercialising our OXPzero technology and are now implementing a clinical trial program to enable the marketing authorisation for at least two products containing our OXPzero ibuprofen salt.

2013 has been a transformational year for us and we are now well placed to push on in 2014 with our clinical and commercial programs for a wide range of 'GI safe' NSAIDs and safer statins"

For further information:

Oxford Pharmascience Group Plc

Nigel Theobald, Chief Executive +44 207 554 5875

N+1 Singer

Shaun Dobson +44 20 7496 3000

About Oxford Pharmascience Group Plc

Oxford Pharmascience Group Plc uses a range of proprietary technology platforms to re-develop existing medicines to make them better, safer or easier to take. The Company does not manufacture or sell its own pharmaceutical products direct to consumers but instead seeks to license its technologies and dossiers to a network of partners, mainly leading pharmaceutical companies with Rx (prescription) and OTC (Over the Counter) branded portfolios.

Oxford Pharmascience Group Plc focuses on existing medicines that are proven to be safe and effective but nevertheless still have associated issues and side effects often affecting compliance. By working with such medicines the Company is able to develop new innovative products for a fraction of the cost, in much quicker timescales and without the high risk of failure associated with developing new drugs.